New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2013
09:01 EDTDNDNDendreon's Provenge still facing headwinds, says RW Baird
Baird's Provenge checks continue to show slow acceptance, slower than expected pace for expense savings, and concerns surrounding competition. The firm recommends staying on the sidelines in Dendreon shares and maintatins its Neutral rating and $6 price target.
News For DNDN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 16, 2014
09:13 EDTDNDNNICE says Dendreon drug too expensive for prostate cancer use
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use